Patent intelligence · US
US 11883433
Chimeric antigen receptor comprising anti-mesothelin scFv, and use thereof
Chimeric antigen receptor comprising anti-mesothelin scFv, and use thereof
Patent details — US 11883433
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 30, 2024
- Expiration
- Jan 25, 2044
- Applicant
- CELLENGENE INC.
- Claims
- 16
- CPC classes
- A61K, A61K2039/505, A61K2239/11, A61K2239/21
Quick answer
US 11883433 (Chimeric antigen receptor comprising anti-mesothelin scFv, and use thereof) is held by CELLENGENE INC.. Status: granted. Granted Jan 30, 2024. Expires Jan 25, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CELLENGENE INC.
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K2039/505, A61K2239/11, A61K2239/21, A61K2239/31, A61K2239/59
More from CELLENGENE INC.
Related pharmaceutical patents in our USPTO index.
-
US 12421273
Ectonucleotidase inhibitors and methods of use thereof
granted -
US 12414968
Compositions comprising bacterially derived minicells and methods of using the same
granted -
US 12357687
Compositions and vaccines for treating and/or preventing viral infections, and methods of using the same
granted -
US 12337033
Encapsulated glycolipid antigens for treatment of neoplastic diseases
granted -
US 12076418
Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo
granted -
US 11964021
Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
granted -
US 11858957
Ectonucleotidase inhibitors and methods of use thereof
granted
Frequently asked questions
What is US patent 11883433?
US 11883433 (Chimeric antigen receptor comprising anti-mesothelin scFv, and use thereof) is held by CELLENGENE INC.. Status: granted. Granted Jan 30, 2024. Expires Jan 25, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11883433?
CELLENGENE INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 53 pharmaceutical patents for this assignee.
When does US 11883433 expire?
Our index shows an expiration date of Jan 25, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.